Cinda Bio publishes the results of phase 3 double-blind phase 3 of IBI305 treatment for advanced non-squamous non-small cell lung cancer

recently, cinda Bio
Pharmaceutical s
(http://(http://announced the results of the study of the effectiveness and safety of IBI305 (bevalbea mono-antibiotic) and beva-beth-single anti-co-purple alcohol/caplatinum first-line treatment of patients with advanced non-squamous non-small cell lung cancer (CTR20160848)About CTR20160848
CTR20160848 study a total of 450 patients enrolled in the group, of which IBI305 (n-224) and reference drug bevanbezumab (RBv) group (n-226), as of March 31, 2019, the fullanalysis(http://Set (FAS) full analysis set (FAS) set, the updated objective mitigation rate (ORR) evaluated by the central image was 47.1% and 46.8%, respectively, and the ORR ratio was 1.01 (90% CI:0.846, 1.181), falling in the equivalent boundary value (0.75, 1.33) as specified in the research schemeAs of May 22, 2019, the results showed that the median PFS in the IBI305 and RBv groups assessed by the researchers was 7.3 months and 7.5 months, respectively, with no statistical differences (p.893)About IBI305
IBI305 is a biosimilar drug of beva-pearl mono-anti-injection, also known as recombinant anti-VEGF humanized monoclonal antibody injectionVEGF is an important factor in angiogenesis, which is over-pathologically expressed in endothelial cells of most human tumorsAnti-VEGF antibodies, which can be highly affinityally selectively bind to VEGF, block the conduction of signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK by blocking the binding of VEGF to receptors on the surface of its vascular endothelial cellsIn order to inhibit the growth, proliferation and migration of vascular endothelial cells and the rebirth of blood vessels, reduce vascular permeability, block the blood supply of tumor tissue (http:// , inhibit the proliferation and metastasis of tumor cells, induce tumor cell apoptosis, so as to achieve anti-tumor treatment effect 　　On 29 January 2019, IBI305's application for the listing of New Drug (http:// (NDA) was accepted by the National Medicines (http:// Regulatory Authority (NMPA) and included in the priority review